RETATRUTIDE

Overview:

Retatrutide is a synthetic modified peptide investigated as a multi-receptor incretin and glucagon pathway agonist. It is commonly described as a triple agonist of the glucagon-like peptide-1 receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon receptor.

Scientific interest around retatrutide comes from its combined receptor pharmacology across GLP-1, GIP, and glucagon signaling systems. These receptor pathways are involved in metabolic regulation, insulin secretion models, appetite and energy-balance models, and hepatic glucose and lipid metabolism research.

Retatrutide is an investigational metabolic peptide in clinical research settings. It should be discussed in terms of receptor pharmacology, clinical-trial research, and investigational status rather than general product claims.

Mechanism Overview:

Retatrutide has been investigated as a triple agonist targeting GLP-1R, GIPR, and GCGR. GLP-1 receptor signaling is commonly associated with incretin and appetite-related pathways, GIP receptor signaling with incretin and adipose/metabolic biology, and glucagon receptor signaling with hepatic energy metabolism. These mechanisms are being studied in clinical development contexts and should not be presented as established claims outside regulatory approval and labeled use.

Structure:

· CAS: 2381089-83-2

· Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys-Ala-Gln-Ala-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

· Molecular Weight: ~4731.3 g/mol